SCHEMBL3214616

SCHEMBL3214616

Nc1ncccc1CNc1cccc(Oc2cc(=O)[nH]c3ccccc23)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.45
GAA P10253 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PTK6 Q13882 2/20 0.40
GRM5 P41594 1/20 0.37
MAPT P10636 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
BRAF P15056 3/20 0.36
IDH1 O75874 1/20 0.36
KDM4E B2RXH2 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 1/20 0.35
ALPG P10696 1/20 0.35
HPGD P15428 1/20 0.35
MAOA P21397 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13428972 0.89 GAA (0.44) GAAMEN1KMT2APTK6GRM5
SCHEMBL3217145 0.87 KMT2A (0.45) GAAMEN1KMT2APTK6GRM5
SCHEMBL13429313 0.87 GAA (0.53) GAAMEN1KMT2APTK6MAPT
SCHEMBL13429358 0.86 MEN1 (0.45) GAAMEN1KMT2APTK6GRM5
SCHEMBL13429256 0.84 MAOA (0.44) GAAMEN1KMT2APTK6GRM5
SCHEMBL13429381 0.84 MEN1 (0.44) GAAMEN1KMT2APTK6GRM5
SCHEMBL13429366 0.84 MEN1 (0.43) GAAMEN1KMT2APTK6GRM5
SCHEMBL3222479 0.82 MEN1 (0.41) GAAMEN1KMT2AMAPTNPSR1
SCHEMBL13429262 0.81 F2 (0.46) GAAMEN1KMT2APTK6LMNA
SCHEMBL13429368 0.81 MEN1 (0.42) GAAMEN1KMT2APTK6GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US claimed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA VCP 1328/4885GAA 1227/4885MEN1 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.